Abstract:Outcomes 1. Understand the prevalence of high-intensity healthcare utilization among individuals with advanced-stage melanoma and lung cancer receiving ICIs. 2. Recognize 2-3 patient characteristics that may influence high-intensity healthcare utilization among individuals with advanced-stage melanoma and lung cancer receiving ICIs. Key Message Immune checkpoint inhibitor receipt was associated with increased emergency department and inpatient encounters among individuals with advanced lung cancer and melanoma diagnosed between 2013-2018 and followed to 2021. Over 13% of individuals who died within the study period had inpatient emergency department encounters within the last six months of life. Importance Immune checkpoint inhibitors (ICI) have become standard of care in advanced melanoma and lung cancers. ICIs have lower toxicities than chemotherapy but adverse effects are common. Around 4-28% of ICI patients experience severe adverse events requiring inpatient care, making this patient population at potentially greater risk for high intensity care utilization. Objective(s) We examined the risk of all-cause inpatient and emergency department visits among melanoma and lung cancer ICI patients, hypothesizing that ICI receipt would be associated with greater healthcare utilization. Scientific Methods Utilized Patients diagnosed between 2013-2018 were identified with the Utah Cancer Registry and ICI receipt and health encounters were identified with the Utah All-Payers Claims Database and statewide inpatient and emergency department records. Bivariate tests and multivariable Poisson Regression Models were conducted in R (p < 0.05). Results 415 patients with melanoma (n=137, 33%) and lung cancer (n=278, 67%) received a PD-1/PD-L1 or CTLA-4 ICI between 2013 and 2021. Most were diagnosed at distant stages of disease (68.9%) and had a median of 2 (IQR=1-3) inpatient stays and 1 (IQR= 0-3) emergency department visits. Accounting for demographics, socioeconomic characteristics, rurality, cancer stage, and non-cancer comorbidities, ICI receipt was associated with increased emergency department visits among melanoma (aIRR= 1.71, 95% CI=1.48-1.98, p< 0.001) and lung cancer patients (aIRR=1.37, 95% CI=1.24-1.51, p< 0.001). ICI receipt was also associated with increased inpatient stays (melanoma aIRR=1.47, 95% CI= 1.27-1.71, p< 0.001; lung cancer aIRR=1.37, 95% CI=1.25-1.50, p< 0.001). Of the 302 ICI patients who died within the study period, 41 (13.6%) had inpatient or emergency department encounters in the last six months of life. Conclusion(s) Patients receiving ICIs may have increased risk for inpatient and emergency department use. Impact Findings have implications for symptom monitoring, management, and decision-making support among ICI patients. Future directions will examine causes of admissions and palliative care use among decedents receiving ICIs.

Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors

1106P International Experience of Ipilimumab and Nivolumab in Patients with Advanced Melanoma

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy

The relationship between immune-related adverse events during ipilimumab monotherapy and survival outcomes among melanoma patients: A systematic review

Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma

Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real‐world, multicenter, retrospective study

Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors

Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors

Inpatient and ED Use Among Melanoma and Lung Cancer Patients Receiving Immune Checkpoint Inhibitors (GP133)

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes

The safety of anti PD-1 therapeutics for the treatment of melanoma

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy

Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare Data

Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients

Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution